Eli Lilly beats revenue and earnings estimates as stock falls 7.2% over month
AI Summary- Eli Lilly reported a quarter beating revenue and earnings estimates.
- 7.2% was the stock’s decline over the past month.
- Mounjaro and Zepbound drove results as GLP-1 drugs for obesity and diabetes.